We’re delighted to welcome Professor Jackie Hunter CBE as Corporate Advisor to PharmEnable. Jackie’s deep experience in pharma R&D, strategic partnerships and AI-driven innovation will be invaluable as PharmEnable advances its pipeline and collaborations.
Jackie brings over 30 years of leadership experience in pharmaceutical and bioscience R&D, spanning industry, public research funding and AI-enabled drug discovery. At GlaxoSmithKline she served as Senior Vice-President, leading neurology and gastrointestinal drug discovery. She later became Chief Executive of the UK Biotechnology and Biological Sciences Research Council (BBSRC), before joining BenevolentBio as CEO, where she established the pharmaceutical R&D arm of BenevolentAI and went on to serve on the BenevolentAI board until 2023.
She has recently held several senior non-executive and chair roles, including Chair of Stevenage Bioscience Catalyst, Chair of Brainomix and Biocortex. Jackie is currently a board member of A*STAR and Chair of the Digital Health Accelerator Board in Singapore. She has received multiple awards and honorary doctorates, is a Fellow of the Academy of Medical Sciences and other leading UK scientific societies, and was appointed CBE for services to the pharmaceutical industry.
We are very pleased to welcome her to PharmEnable and look forward to working with her as we progress our next generation of small molecule medicines.